Initiator Pharma A/S

OM:INIT Stock Report

Market Cap: SEK 390.9m

Initiator Pharma Management

Management criteria checks 4/4

Initiator Pharma's CEO is Claus Olesen, appointed in May 2016, has a tenure of 8.67 years. total yearly compensation is DKK1.29M, comprised of 66.2% salary and 33.8% bonuses, including company stock and options. directly owns 4.04% of the company’s shares, worth SEK15.81M. The average tenure of the management team and the board of directors is 8.8 years and 6.2 years respectively.

Key information

Claus Olesen

Chief executive officer

DKK 1.3m

Total compensation

CEO salary percentage66.2%
CEO tenure8.7yrs
CEO ownership4.0%
Management average tenure8.8yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

May 31
We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

Feb 27
Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

May 20
Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Jan 06
Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Oct 26
We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Jun 12
We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

CEO Compensation Analysis

How has Claus Olesen's remuneration changed compared to Initiator Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-DKK 11m

Jun 30 2024n/an/a

-DKK 12m

Mar 31 2024n/an/a

-DKK 18m

Dec 31 2023DKK 1mDKK 857k

-DKK 23m

Sep 30 2023n/an/a

-DKK 27m

Jun 30 2023n/an/a

-DKK 29m

Mar 31 2023n/an/a

-DKK 33m

Dec 31 2022DKK 1mn/a

-DKK 38m

Sep 30 2022n/an/a

-DKK 40m

Jun 30 2022n/an/a

-DKK 43m

Mar 31 2022n/an/a

-DKK 34m

Dec 31 2021DKK 1mn/a

-DKK 21m

Sep 30 2021n/an/a

-DKK 16m

Jun 30 2021n/an/a

-DKK 10m

Mar 31 2021n/an/a

-DKK 8m

Dec 31 2020DKK 936kn/a

-DKK 9m

Sep 30 2020n/an/a

-DKK 10m

Jun 30 2020n/an/a

-DKK 9m

Mar 31 2020n/an/a

-DKK 9m

Dec 31 2019DKK 662kn/a

-DKK 8m

Compensation vs Market: Claus's total compensation ($USD178.49K) is about average for companies of similar size in the Swedish market ($USD228.21K).

Compensation vs Earnings: Claus's compensation has been consistent with company performance over the past year.

CEO

Claus Olesen (50 yo)

8.7yrs

Tenure

DKK 1,293,200

Compensation

Dr. Claus Elsborg Olesen is Chief Executive Officer at Stipe Therapeutics. He serves Chief Executive Officer at Initiator Pharma A/S since May 02, 2016 and serves as its Director since September 19, 2016 a...

Leadership Team

NamePositionTenureCompensationOwnership
Claus Olesen
Co-Founder8.7yrsDKK 1.29m4.04%
SEK 15.8m
Dan Peters
Co-Founder & CTO9yrsno datano data
Ulf Simonsen
Co-Founderno datano data1.16%
SEK 4.5m
Mikael Thomsen
Co-Founder & Chief Development Officerno datano data1.34%
SEK 5.2m
Torgeir Vaage
Chief Financial Officer9yrsno datano data
Allan Wehnert
Senior Vice President of Clinical and R&D Strategy & Portfolio Management4.1yrsno datano data
Susanne Thomsen
Head of Clin Opsno datano datano data
Rene Egebro
Head of CMCno datano datano data

8.8yrs

Average Tenure

60yo

Average Age

Experienced Management: INIT's management team is seasoned and experienced (8.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Claus Olesen
Co-Founder8.3yrsDKK 1.29m4.04%
SEK 15.8m
Gunnar Magnus Severus Persson
Chairman of the Board of Directors8.3yrsDKK 220.00k0.48%
SEK 1.9m
Henrik Moltke
Director8.3yrsDKK 90.00k0.25%
SEK 966.8k
Irwin Goldstein
Member of Scientific & Clinical Advisory Board4.1yrsno datano data
Gunilla Ekstrom
Independent Director2.3yrsDKK 90.00k0.034%
SEK 132.0k
Annette Colin
Director4yrsDKK 90.00k0.71%
SEK 2.8m
Peter Holm
Director8.3yrsDKK 90.00kno data
Sue Goldstein
Member of Scientific & Clinical Advisory Board4.1yrsno datano data

6.2yrs

Average Tenure

61.5yo

Average Age

Experienced Board: INIT's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 07:11
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Initiator Pharma A/S is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Klas PalinPenser Access
Kevin SuleRedeye